Project description:Angiosarcomas are ultra-rare, highly aggressive sarcomas with limited treatment options and dismal prognosis. In this project, we quantified immune cell infiltrates in the angiosarcoma tumor microenvironment. Unsupervised clustering was applied to reveal prognostically significant immune phenotypes. Proteomic profiling of 88 angiosarcoma samples (54 primary tissue, 17 local relapse tissue, and 17 metastatic tissue), 20 benign control tissues and 9 pooled groups was performed by LC–MS/MS to compare various AS subtypes, as well as up- and downregulated pathways between immune cell clusters.
Project description:Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.